The purpose of this study is to determine the impact of edema on the dose delivered to the target volume. An evaluation of the edema characteristics was first made, and then a dynamical dosimetry algorithm was developed and used to compare its results to a standard clinical (static) dosimetry. Source positions and prostate contours extracted from 66 clinical cases on images taken at different points in time (planning, implant day, post-implant evaluation) were used, via the mean interseed distance, to characterize edema [initial increase (deltar0), half-life (tau)]. An algorithm was developed to take into account the edema by summing a time series of dose-volume histograms (DVHs) with a weight based on the fraction of the dose delivered during the time interval considered. The algorithm was then used to evaluate the impact of edema on the dosimetry of permanent implants by comparing its results to those of a standard clinical dosimetry. The volumetric study yielded results as follows: the initial prostate volume increase was found to be 1.58 (ranging from 1.15 to 2.48) and the edema half-life, approximately 30 days (range: 3 to 170 days). The dosimetric differences in D90 observed between the dynamic dosimetry and the clinical one for a single case were up to 15 Gy and depended on the edema half-life and the initial volume increase. The average edema half-life, 30 days, is about 3 times longer than the previously reported 9 days. Dosimetric differences up to 10% of the prescription dose are observed, which can lead to differences in the quality assertion of an implant. The study of individual patient edema resorption with time might be necessary to extract meaningful clinical correlation or biological parameters in permanent implants.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1118/1.2168066 | DOI Listing |
Am J Vet Res
January 2025
Department of Large Animal Medicine and Surgery, College of Veterinary Medicine, University of Georgia, Athens, GA.
Objective: To investigate the disposition of enrofloxacin and its active metabolite, ciprofloxacin, in plasma, pulmonary epithelial lining fluid (PELF), peritoneal fluid, and CSF in horses following IV administration of enrofloxacin at doses of 5 mg/kg and 7.5 mg/kg of body weight.
Methods: 6 healthy, mature mares were randomly assigned to receive a single dose of enrofloxacin at either 5 mg/kg or 7.
Biomacromolecules
January 2025
MOE Key Laboratory of Macromolecular Synthesis and Functionalization, Department of Polymer Science and Engineering, Zhejiang University, Hangzhou 310058, China.
-Acetyl cysteine (NAC) is an essential molecule that boosts acute lung injury (ALI) defense via its direct antioxidant capability. Nevertheless, the therapeutic use of NAC is limited due to its poor bioavailability and short half-life. In this study, NAC was grafted to the polyurethane consisting of poly(propylene fumarate), poly(thioketal), and 1,6-hexamethylene diisocyanate (PFTU) to reduce excessive oxidative stress and inflammatory factors in ALI.
View Article and Find Full Text PDFJ Biomater Sci Polym Ed
December 2024
Department of Pharmaceutics, Dr. Prabhakar B Kore Basic Science Research Center, Off-campus, KLE College of Pharmacy (A constituent unit of KAHER-Belagavi), Bengaluru, Karnataka, India.
Zaltoprofen (ZAL) is a non-steroidal anti-inflammatory drug (NSAID) with a short half-life (∼2.8 h) due to extensive first pass metabolism. In this context, 16 different polymeric film forming solutions (PFFS) of ZAL were developed using different grades of Eudragits, Polyvinylpyrrolidones, Kollicoat MAE 100 P and Hydroxypropyl cellulose as film formers, and polyethylene glycol 400 as a plasticizer in equal parts of ethanol and isopropyl alcohol used as solvents.
View Article and Find Full Text PDFCureus
November 2024
Ophthalmology, Institute of Ophthalmology, Joseph Eye Hospital, Tiruchirappalli, IND.
Aim: This study aims to compare the effects of intravitreal triamcinolone acetonide (IVTA) and bevacizumab (IVB) in diabetic macular edema (DME) management.
Methodology: A prospective interventional study was conducted at a tertiary eye care hospital in Tamil Nadu, India. The study received approval from the institutional ethics committee, and informed consent was obtained from all participants.
Mol Cancer Ther
December 2024
Massachusetts General Hospital, Boston, Massachusetts, United States.
Src homology-2 domain-containing phosphatase 2 (SHP2) promotes RAS-MAPK signaling and tumorigenesis and is a promising therapeutic target for multiple solid tumors. Migoprotafib is a potent and highly selective SHP2 inhibitor designed for the treatment of RAS-MAPK driven cancers, particularly in combination with other targeted agents. Here we report first-in-human study results of single agent migoprotafib in advanced solid tumor patients.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!